Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 5Phase 1/2 3Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 1

Conditions

Sarcoma 2Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × olaratumab × Clear all
NCT03086369 2022-06-28

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
184 enrolled 22 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02659020 2022-05-09

ANNOUNCE 2

Eli Lilly and Company

Phase 1/2 Completed
310 enrolled 33 charts
Sarcoma

Sarcoma

NCT01185964 2017-04-14

A Study of Olaratumab in Soft Tissue Sarcoma

Eli Lilly and Company

Phase 1/2 Completed
148 enrolled 21 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡